Amplify Weight Loss Drug & Treatment ETF (THNR)
| Assets | $3.12M |
| Expense Ratio | 0.59% |
| PE Ratio | 33.83 |
| Shares Out | 120,000 |
| Dividend (ttm) | n/a |
| Dividend Yield | n/a |
| Ex-Dividend Date | n/a |
| Payout Ratio | n/a |
| 1-Year Return | n/a |
| Volume | 4,521 |
| Open | 25.99 |
| Previous Close | 26.19 |
| Day's Range | 25.92 - 26.04 |
| 52-Week Low | 24.92 |
| 52-Week High | 26.43 |
| Beta | 0.17 |
| Holdings | 30 |
| Inception Date | May 21, 2024 |
About THNR
Fund Home PageThe Amplify Weight Loss Drug & Treatment ETF (THNR) is an exchange-traded fund that is based on the VettaFi Weight Loss Drug index. The fund tracks a modified market cap-weighted index of companies from developed markets that manufacture and enable GLP-1 agonist pharmaceutical businesses. THNR was launched on May 21, 2024 and is issued by Amplify Investments.
Top 10 Holdings
71.28% of assets| Name | Symbol | Weight |
|---|---|---|
| Eli Lilly and Company | LLY | 15.18% |
| Novo Nordisk A/S | NVO | 14.43% |
| AstraZeneca PLC | AZN | 7.07% |
| Amgen Inc. | AMGN | 5.14% |
| Chugai Pharmaceutical Co Ltd | 4519.T | 5.01% |
| Pfizer Inc. | PFE | 5.01% |
| Roche Holding AG | ROG.SW | 4.94% |
| FUJIFILM Holdings Corp | 4901.T | 4.88% |
| Merck & Co., Inc. | MRK | 4.85% |
| West Pharmaceutical Services, Inc. | WST | 4.77% |
News
Top Themes in the First Half of 2024: Crypto, Chips, Ships & Silver
After a torrid risk-on run in the first quarter of 2024, markets cooled off a bit but ended the half still positive with mid-double-digit returns. Technology themes such as cryptocurrency and artifici...
Why Investors Haven't Feasted on Two New Weight-Loss ETFs
Two new weight-loss exchange-traded funds (ETFs) launched in May have yet to whet investors' appetite, possibly due to their expensive fees and concentrated bets.
Amplify Debuts New Weight Loss Drug ETF
On Tuesday, Amplify entered the weight loss ETF space with the launch of the Amplify Weight Loss Drug & Treatment ETF (THNR). THNR operates with a net expense ratio of 0.59%.